共 121 条
[1]
Brahmer J(2015)Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 123-135
[2]
Reckamp KL(2015)Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer N Engl J Med 373 1627-1639
[3]
Baas P(2017)Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies Nat Rev Endocrinol 13 195-207
[4]
Borghaei H(2019)A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors Horm Metab Res 51 145-156
[5]
Paz-Ares L(2015)Vitiligo-like depigmentation in patients with stage III–IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis J Clin Oncol 33 773-781
[6]
Horn L(2015)Pembrolizumab cutaneous adverse events and their association with disease progression JAMA Dermatol 151 1206-1212
[7]
Byun DJ(2016)Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab JAMA Dermatol 152 45-51
[8]
Wolchok JD(2019)Thyroid dysfunction, recovery, and prognosis in melanoma patients treated with immune checkpoint inhibitors: a retrospective review Endocr Pract 26 36-42
[9]
Rosenberg LM(2015)Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Lancet Oncol 16 257-265
[10]
Girotra M(2017)Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial Lancet Oncol 18 599-610